Patents by Inventor Jack Urquhart Flanagan

Jack Urquhart Flanagan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tricyclic heterocyclic derivatives and uses thereof
    Patent number: 11028064
    Abstract: Disclosed are tricyclic heterocyclic compounds having kinase inhibitory activity, pharmaceutical compositions and kits comprising the compounds, and use of the compounds in the treatment of or in medicaments for the treatment of various diseases and conditions. In particular, disclosed are tricyclic heterocyclic compounds of the formula (I) having CSF-1R (c-FMS kinase) inhibitory activity and their use in the treatment of various diseases and conditions, such as those mediated by CSF-1R, including proliferative or neoplastic diseases and conditions, including cancers, and bone, inflammatory, and autoimmune diseases and conditions.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 8, 2021
    Assignee: AUCKLAND UNISERVICES LIMITED
    Inventors: Swarnalatha Akuratiya Gamage, Peter Robin Shepherd, Jack Urquhart Flanagan, Gordon William Rewcastle, Andrew James Marshall, Christina Maree Buchanan, Guo-Liang Lu, Muriel Bonnet, Stephen Michael Frazer Jamieson, William Alexander Denny
  • TRICYCLIC HETEROCYCLIC DERIVATIVES AND USES THEREOF
    Publication number: 20190276423
    Abstract: Disclosed are tricyclic heterocyclic compounds having kinase inhibitory activity, pharmaceutical compositions and kits comprising the compounds, and use of the compounds in the treatment of or in medicaments for the treatment of various diseases and conditions. In particular, disclosed are tricyclic heterocyclic compounds of the formula (I) having CSF-1R (c-FMS kinase) inhibitory activity and their use in the treatment of various diseases and conditions, such as those mediated by CSF-1R, including proliferative or neoplastic diseases and conditions, including cancers, and bone, inflammatory, and autoimmune diseases and conditions.
    Type: Application
    Filed: November 3, 2017
    Publication date: September 12, 2019
    Applicant: AUCKLAND UNISERVICES LIMITED
    Inventors: Swarnalatha Akuratiya GAMAGE, Peter Robin SHEPHERD, Jack Urquhart FLANAGAN, Gordon William REWCASTLE, Andrew James MARSHALL, Christina Maree BUCHANAN, Guo-Liang LU, Muriel BONNET, Stephen Michael Frazer JAMIESON, William Alexander DENNY
  • Bacterial nitroreductase enzymes and methods relating thereto
    Patent number: 10357577
    Abstract: The invention relates generally to bacterial nitroreductase enzymes and methods of use thereof: more particularly, although not exclusively, the enzymes have use in non-invasive imaging techniques, monitoring of therapeutic cell populations and gene-directed enzyme prodrug therapy. The invention also relates to the use of bacterial nitroreductase enzymes in radioimaging and/or ablation of biological agents and to compositions of use in such methods.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: July 23, 2019
    Assignees: AUCKLAND UNISERVICES LIMITED, VICTORIA LINK LIMITED
    Inventors: Christopher Paul Guise, David Francis Ackerley, Amir Ashoorzadeh, Janine Naomi Copp, Jack Urquhart Flanagan, Alexandra Marie Mowday, Adam Vorn Patterson, Gareth Adrian Prosser, Jeffrey Bruce Smaill, Sophie Phillipa Syddall, Elsie May Williams
  • Haematopoietic-prostaglandin D2 synthase inhibitors
    Patent number: 9199976
    Abstract: The present invention generally relates to compounds that inhibit haematopoietic-prostaglandin D2 synthase (H-PGDS), to compositions containing them and to their use in treating or preventing conditions and diseases associated with H-PGDS, such as allergies and inflammation.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: December 1, 2015
    Assignee: The University of Queensland
    Inventors: Mark Leslie Smythe, Jack Urquhart Flanagan
  • Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
    Patent number: 9108980
    Abstract: Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: August 18, 2015
    Assignee: VETDC, INC.
    Inventors: Gordon William Rewcastle, Swarnalatha Akuratiya Gamage, Jack Urquhart Flanagan, Anna Claire Giddens, Kit Yee Tsang
  • PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY
    Publication number: 20150038486
    Abstract: Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.
    Type: Application
    Filed: July 7, 2014
    Publication date: February 5, 2015
    Inventors: Gordon William Rewcastle, Swarnalatha Akuratiya Gamage, Jack Urquhart Flanagan, Anna Claire Giddens, Kit Yee Tsang
  • Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
    Patent number: 8772287
    Abstract: Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: July 8, 2014
    Assignee: VetDC, Inc.
    Inventors: Gordon William Rewcastle, Swarnalatha Akuratiya Gamage, Jack Urquhart Flanagan, Anna Claire Giddens, Kit Yee Tsang
  • BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO
    Publication number: 20130295011
    Abstract: The invention relates generally to bacterial nitroreductase enzymes and methods of use thereof: More particularly, although not exclusively, said enzymes have use in non-invasive imaging techniques, monitoring of therapeutic cell populations and gene-directed enzyme prodrug therapy. The invention also relates to the use of bacterial nitroreductase enzymes in radioimaging and/or ablation of biological agents and to compositions of use in such methods.
    Type: Application
    Filed: July 18, 2011
    Publication date: November 7, 2013
    Applicants: VICTORIA LINK LIMITED, AUCKLAND UNISERVICES LIMITED
    Inventors: Christopher Paul Guise, David Francis Ackerley, Amir Ashoorzadeh, Janine Naomi Copp, Jack Urquhart Flanagan, Alexandra Marie Mowday, Adam Vorn Patterson, Gareth Adrian Prosser, Jeffrey Bruce Smaill, Sophie Phillipa Syddall, Elsie May Williams
  • PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY
    Publication number: 20130289016
    Abstract: Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.
    Type: Application
    Filed: June 10, 2013
    Publication date: October 31, 2013
    Inventors: Gordon William Rewcastle, Swarnalatha Akuratiya Gamage, Jack Urquhart Flanagan, Anna Claire Giddens, Kit Yee Tsang
  • Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
    Patent number: 8461158
    Abstract: Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: June 11, 2013
    Assignee: Pathway Therapeutics Inc.
    Inventors: Gordon William Rewcastle, Swarnalatha Akuratiya Gamage, Jack Urquhart Flanagan, Anna Claire Giddens, Kit Yee Tsang
  • HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS
    Publication number: 20130137684
    Abstract: The present invention generally relates to compounds that inhibit haematopoietic-prostaglandin D2 synthase (H-PGDS), to compositions containing them and to their use in treating or preventing conditions and diseases associated with H-PGDS, such as allergies and inflammation.
    Type: Application
    Filed: June 1, 2011
    Publication date: May 30, 2013
    Applicant: THE UNIVERSITY OF QUEENSLAND
    Inventors: Mark Leslie Smythe, Jack Urquhart Flanagan
  • PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY
    Publication number: 20100249099
    Abstract: Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.
    Type: Application
    Filed: March 26, 2010
    Publication date: September 30, 2010
    Applicant: Pathway Therapeutics Limited
    Inventors: Gordon William Rewcastle, Swarnalatha Akuratiya Gamage, Jack Urquhart Flanagan, Anna Claire Giddens, Kit Yee Tsang